SCHEMBL4833950

SCHEMBL4833950

NC1c2ccsc2N=CN1c1ccc(NC(=O)c2cc(F)ccc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 3/20 0.41
▸ RAB9A P51151 6/20 0.40
▸ NPC1 O15118 5/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ CTDSP1 Q9GZU7 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.36
▸ BRAF P15056 1/20 0.35
▸ ANO1 Q5XXA6 1/20 0.35
▸ ANO2 Q9NQ90 1/20 0.35
▸ LCLAT1 Q6UWP7 1/20 0.35
▸ SNCA P37840 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MCL1 Q07820 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4825766 0.84 MAPK8 (0.47) RAB9AANO1ALDH1A1SMN1; SMN2MEN1
SCHEMBL4826966 0.83 JAK2 (0.43) RAB9ANPC1MAPTLMNAHTT
SCHEMBL4833898 0.80 MAPT (0.50) RAB9ANPC1MAPTLMNAMAPK1
SCHEMBL4826281 0.79 RAB9A (0.48) GRM5RAB9ANPC1MAPTHTT
SCHEMBL4826378 0.77 CA12 (0.49) KDRMET
SCHEMBL4826358 0.77 GRM4 (0.34) RAB9ANPC1MAPTLMNAALDH1A1
SCHEMBL4828962 0.76 CSF1R (0.39) LMNAANO1HTT
SCHEMBL4825704 0.76 TRPV1 (0.48) MAPTLMNAHTTTP53SMN1; SMN2
SCHEMBL4831435 0.75 NPC1 (0.51) RAB9ANPC1TDP1MAPTLMNA
SCHEMBL4833679 0.75 GRM5 (0.47) GRM5BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK GRM5 2797/4885RAB9A 3248/4885NPC1 4117/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR GRM5 2110/4885RAB9A 4166/4885NPC1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback